Epimmune Inc. (EPMN) And IDM S.A. Agree To Combine Businesses
10/19/2005 5:13:01 PM
More...
|
Immuno-Designed Molecules Signs An R&D Agreement On Anti-Cancer Vaccine With The Walter Reed Army Institute of Research
10/19/2005 5:12:06 PM
More...
|
The FDA Has Authorized IDM, Inc. To Start A Phase II Trial In The United States On Its Therapeutic Vaccine Uvidem
10/19/2005 5:11:36 PM
More...
|
IDM, Inc. Announces The Opening Of Its cGMP Production Center In The United States
10/19/2005 5:10:58 PM
More...
|
IDM S.A. Will Present Phase II Trial Results For Its Melanoma Cancer Vaccine, Uvidem, At American Society of Clinical Oncology - Orlando - On May 15, 2005
10/19/2005 5:10:30 PM
More...
|
IDM, Inc. Announces Detailed Phase III Results For Mepact In Osteosarcoma To Be Presented At ASPHO Annual Meeting
10/19/2005 5:10:20 PM
More...
|
IDM, Inc. Obtains A European Patent Protecting The Basic Technology Behind Its Therapeutic Vaccines
10/19/2005 5:09:50 PM
More...
|
IDM And Cambridge Laboratories Limited Sign An Exclusive Marketing Agreement For Junovan(TM) (Mepact) In The United Kingdom And Ireland
10/19/2005 5:09:19 PM
More...
|
Mepact, IDM, Inc.'s Most Advanced Product, Receives "Orphan Medicinal Product" Designation For The Treatment Of Osteosarcoma In The European Union
10/19/2005 5:08:58 PM
More...
|
IDM, Inc. Announces Appointment Of Guy-Charles Fanneau de la Horie As Vice-President, Director France
10/19/2005 5:08:56 PM
More...
|